Capsaicin

• A randomized, double-blind, placebo-controlled study to assess the effects of high concentration capsaicin patch (Qutenza) on neuropathic sy… Pending
  2025-523597-17-00 Phase II 1 country Deutsche Diabetes Forschungsgesellschaft e.V.
• SerCaBot-2302 - Serratus Plane Block (SPB) versus Capsaicin versus Botulinum toxin type A for the chronic neuropathic pain of post-mastectom… Recruiting
  2024-517420-20-00 Phase II 1 country Centre Oscar Lambret
• Capsaicin in digital osteoarthritis versus control : a randomized study Recruiting
  2024-511159-16-00 Phase IV 1 country University Hospital Of Clermont-Ferrand
• CAPSAPED Recruiting
  2022-500265-27-00 Phase III 1 country Centre Hospitalier Regional Et Universitaire De Brest
• Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric… Recruiting
  2023-504618-31-00 Phase III 1 country Institut De Cancerologie De L Ouest
• Prospective, randomized, blinded, comparative study between botulinum toxin and topical capsaicin in the treatment of postmastectomy syndrom… Ended
  2024-513609-29-01 Phase IV 1 country Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comuni…
• The rimegePant in RElation to obeSiTy in mIGrainE study Ended
  2024-513359-34-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended
  2022-500898-13-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
• A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended
  2024-514934-19-00 Phase III 4 countries Averitas Pharma Inc.
• Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae … Ended
  2024-515510-41-00 Phase II 1 country Oncopole Claudius Regaud

Showing 1–11 of 11 trials